These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30108860)

  • 1. Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy.
    Luo J; Hu Z; Xiao Y; Yang T; Dong C; Huang J; Zhou HB
    Medchemcomm; 2017 Jul; 8(7):1485-1497. PubMed ID: 30108860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selenophenes: Introducing a New Element into the Core of Non-Steroidal Estrogen Receptor Ligands.
    Zhang S; Wang Z; Hu Z; Li C; Tang C; Carlson KE; Luo J; Dong C; Katzenellenbogen JA; Huang J; Zhou HB
    ChemMedChem; 2017 Feb; 12(3):235-249. PubMed ID: 27976818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
    Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
    Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
    Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
    Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
    Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.
    Kelly PM; Keely NO; Bright SA; Yassin B; Ana G; Fayne D; Zisterer DM; Meegan MJ
    Molecules; 2017 Aug; 22(9):. PubMed ID: 28858267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.
    Ragab MA; Elagawany M; Daabees H; Ahmed AF; Awad EM; Billon C; Elgendy B; Abouzid KAM; Kassab SE
    Bioorg Chem; 2022 Feb; 119():105554. PubMed ID: 34923243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
    Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists.
    Stauffer SR; Huang YR; Aron ZD; Coletta CJ; Sun J; Katzenellenbogen BS; Katzenellenbogen JA
    Bioorg Med Chem; 2001 Jan; 9(1):151-61. PubMed ID: 11197335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonists selective for estrogen receptor alpha.
    Sun J; Huang YR; Harrington WR; Sheng S; Katzenellenbogen JA; Katzenellenbogen BS
    Endocrinology; 2002 Mar; 143(3):941-7. PubMed ID: 11861516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
    O'Boyle NM; Barrett I; Greene LM; Carr M; Fayne D; Twamley B; Knox AJS; Keely NO; Zisterer DM; Meegan MJ
    J Med Chem; 2018 Jan; 61(2):514-534. PubMed ID: 28426931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
    Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
    Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
    Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
    Ejaz I; Javed MA; Jan MS; Ikram M; Sadiq A; Ahmad S; Rashid U
    Bioorg Med Chem Lett; 2022 May; 64():128668. PubMed ID: 35276362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
    Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
    J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.